Posted inBiotechnology
After missed endpoint, Gossamer and Chiesi pull the plug on PAH drug collaboration
After signing a deal worth up to $486 million with Italian biopharma Chiesi to develop its pulmonary arterial hypertension (PAH)…
Posted inBiotechnology
Multicenter Large Language Model Predicts Acute Kidney Injury and Explains Risk
A new study promises to change how clinicians anticipate acute kidney injury (AKI) before it becomes irreversible damage, using a…
Posted inBiotechnology
Emerging Capitalism and Cultural Niche Building in Early Modern Greece
A new study of early modern Greece suggests that capitalism did not arrive as a sudden external shock. Instead, it…
Posted inBiotechnology
Immunogenicity and Safety of BNT162b2 in Juvenile Immune-Mediated Inflammatory Disease Patients
A new phase of COVID-19 vaccine evaluation is underway for a group often underrepresented in clinical trials: children and adolescents…
Posted inBiotechnology
PIN1 boosts YAP1 SUMOylation and blocks ferroptosis through autophagy-driven ACSL4 degradation in cervical cancer
In a new study published in Cell Death Discovery, researchers report that the prolyl isomerase PIN1 can tip the balance…
Posted inBiotechnology
Trisomy 13 and 18 Patient Outcomes in a Center With Perinatal Palliative Care Program
A new study in J Perinatology reports what happens to pregnancies affected by trisomy 13 (T13) or trisomy 18 (T18)…
Posted inBiotechnology
Hidden Patterns of Urban Mixing Uncovered in Five Global Cities
Cities are often discussed as mosaics of cultures, but a new study suggests their real mixing is far more patterned—and…
Posted inGenetics
StockWatch: Axiom CEO Explains Plans for Hong Kong IPO
The headquarters of the Hong Kong Exchanges and Clearing Ltd. (HKEX), located within Exchange Square. Axiom Biosciences has announced plans…
Posted inBiotechnology
Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug
Argenx is spending $2.2 billion to absorb Forte Biosciences for its phase 2-stage vitiligo and celiac disease drug.
Posted inBiotechnology
AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates
AstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of ADCs despite scrapping two candidates that…